Claims for Patent: 4,968,603

Summary for Patent: 4,968,603

Title:	Determination of status in neoplastic disease
Abstract:	Amplification of the HER-2/neu oncogene is related to the status of neoplastic diseases, particularly breast and ovarian adenocarcinomas. The presence of multiple gene copies in tumor cells indicates that the disease is more likely to spread beyond the primary tumor site, and that the disease therefore may require more aggressive treatment than might otherwise be indicated by other diagnostic factors. In particular, the degree of gene amplification appears to provide greater prognostic utility than either the estrogen receptor or the progesterone receptor, and provides utility equal to that of the determination of lymph node status. The information provided by the gene amplification test, however, is not duplicative with the determination of lymph node status and the two tests together provide greatly improved prognostic utility.
Inventor(s):	Dennis J. Slamon, William L. McGuire
Assignee:	CALIFORNIA A CA CORP, University of, Regents of , Genentech Inc , University of Texas System , University of California San Diego UCSD
Application Number:	US06/948,265

Details for Patent 4,968,603

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	June 08, 2012	4,968,603	2007-11-06